Cibus’s Gene-Editing Advancements and Global Regulatory Approvals Drive Buy Rating

Analyst Austin Moeller of Canaccord Genuity maintained a Buy rating on Cibus (CBUS – Research Report), retaining the price target of $18.00.

Austin Moeller has given his Buy rating due to a combination of factors, primarily focusing on the recent regulatory advancements concerning Cibus’s gene-editing technology. The United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS) has provided a favorable regulatory status for two of Cibus’s disease resistance traits in Canola, including the Sclerotinia resistance trait. This decision means that these traits, developed using Cibus’s proprietary RTDS gene-editing technology, are not considered “regulated articles” and thus are not subject to certain logistical restrictions.
Furthermore, this regulatory approval aligns with similar frameworks being adopted globally, such as in the European Union and Canada, which treat gene-edited plants similarly to those produced through conventional breeding. This global trend supports the potential for Cibus to expand its market reach. Additionally, Cibus’s management has outlined plans to launch their Sclerotinia resistance trait in the US and Europe by 2029, with an estimated total addressable market for royalties between $300 million and $450 million annually. These strategic developments and market opportunities underpin Moeller’s optimistic outlook and Buy rating for Cibus’s stock.

CBUS’s price has also changed dramatically for the past six months – from $3.680 to $1.990, which is a -45.92% drop .